TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 3BNC117 and 10-1074 in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age 18 to 65.~* Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.~* If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) for the duration of the study.~Exclusion Criteria:~* Confirmed HIV-1 or HIV-2 infection.~* History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.~* Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.~* Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.~* Chronic Hepatitis B or Hepatitis C infection.~* Laboratory abnormalities in the parameters listed:~* Absolute neutrophil count ≤ 2,000;~* Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;~* Platelet count ≤ 125,000;~* Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x ULN;~* Alkaline phosphatase ≥ 1.5 x ULN~* Total bilirubin \> 1.0 x ULN;~* Creatinine ≥1.1 x ULN;~* Pregnancy or lactation.~* Any vaccination within 14 days prior to infusion~* Receipt of any experimental HIV vaccine in the past.~* History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.~* Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
- Group 2 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
- Group 3 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Digital Intervention for HIV Prevention in Black Adolescent Girls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Both phases (includes focus groups- Phase 1)~* Black (race)~* Heterosexual~* Currently enrolled in high school~Pilot Test (Phase 2)~* Ability to participate in web-based videogame~* Willing to sit for at least 60 minutes (to play the game)~* No HIV testing in the last 12 months~* Ability to provide assent or parental/guardian consent~Exclusion Criteria:~* Failure to meet inclusion criteria

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- InvestiDate Intervention (Type: EXPERIMENTAL): One Night Stan will be adapted as a multiplayer videogame called InvestiDate based on the card game prototype with a focus on a slightly younger age group.
- Non-Health Related Game (Type: PLACEBO_COMPARATOR): Participants in the non-health related game group will play a multiplayer game unrelated to the content of InvestiDate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1) at least 18 years of age,~* 2) English or Spanish-speaking,~* 3) stated intent to breastfeed,~* 4) anticipating the birth of a very low birth weight infant (≤1500 grams) between 23-32 weeks gestation.~Exclusion Criteria:~* 1) known illicit maternal drug use,~* 2) history of breast reduction or augmentation,~* 3) positive HIV status,~* 4) mother not transported to recovery by 45 minutes following delivery or~* 5) infant not expected to live over 2 weeks following delivery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Early initiation (Type: EXPERIMENTAL): Initiation of breast milk expression \<1 hour following delivery.
- Intermediate expression (Type: EXPERIMENTAL): Initiation of milk expression 1-\<3 hours following delivery.
- Late initiation (Type: OTHER): Initiation of milk expression \>3-6 hours following delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with a clinical diagnosis of ocular hypertension, or primary open-angle, pigment dispersion or exfoliation glaucoma in at least one eye (study eye)~Exclusion Criteria:~* Age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed the open-label extension study (MVT-601-3003).~2. Is a responder: Has a menstrual blood loss of \< 80 mL AND at least a 50% reduction from the parent study Baseline based on the results of the alkaline hematin testing performed on the feminine products returned at the Week 48 visit of the extension study.~3. Is not expected to undergo gynecological surgery or ablation procedures for uterine fibroids within the study period~Exclusion Criteria:~1. Has undergone myomectomy, ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance guided focused ultrasound for fibroids, or endometrial ablation for abnormal uterine bleeding at any time during the Parent study or extension study.~2. Has a weight that exceeds the weight limit of the dual-energy x-ray absorptiometry (DXA) scanner~3. Has developed any contraindication to treatment with estradiol or norethindrone acetate~4. Is currently pregnant or lactating, or intends to become pregnant during the study period~5. Met a withdrawal criterion in the open-label extension (OLE) study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Type: EXPERIMENTAL): Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
- Placebo tablets and capsules (Type: PLACEBO_COMPARATOR): * Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~* Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA 1. Provision of informed consent prior to any study specific procedures. For patients under-age, signed informed consent from both the patient and the patient's parent/legal guardian is required 2. Male or Female, ≥12 years of age 3. Documented diagnosis of asthma for at least 6 months prior to Visit 1 4. Patients who are in need of Step 2 treatment according to Global Initiative for Asthma guidelines 5. Patients treated with 'as needed' inhaled short-acting bronchodilator(s) only should have pre-bronchodilator Forced Expiratory Volume in one second (FEV1) ≥ 60 % of Predicted Normal (PN) and post-bronchodilator FEV1 ≥ 80 % PN 6. Patients treated with low stable dose of inhaled corticosteroid or leukotriene antagonist in addition to 'as needed' use of inhaled short-acting bronchodilator(s) should have pre-bronchodilator FEV1 ≥80 % PN 7. Patients should have reversible airway obstruction 8. To be randomized patients must have used Bricanyl Turbuhaler 'as needed' on at least 3 separate days during the last week of the run in period. EXCLUSION CRITERIA 1. Patient has a history of life-threatening asthma including intubation and intensive care unit admission 2. Patient has had an asthma worsening requiring change in treatment other than inhaled short-acting bronchodilator(s) within 30 days prior to Visit 1 or between Visits 1 and 2; or a treatment other than Bricanyl Turbuhaler from Visit 2 until randomization 3. Patient has required treatment with oral, rectal or parenteral glucocorticosteroids (GCS) within 30 days and/or depot parenteral GCS within 12 weeks prior to Visit 1 4. Smoker (current or previous) with a smoking history of ≥ 10 pack years 5. Pregnancy, breast-feeding or planned pregnancy during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Symbicort as needed+placebo Pulmicort bid (Type: EXPERIMENTAL): Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
- terbutaline as needed+placebo Pulmicort bid (Type: ACTIVE_COMPARATOR): terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
- Pulmicort bid + terbutaline as needed (Type: ACTIVE_COMPARATOR): Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Subcutaneous Infusion of Pramlintide and Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~These children will be subjects of the Texas Children's Hospital Diabetes Care Center. The subjects must be~1. 13-22 years of age at the time of enrollment.~2. Have been diagnosed with diabetes for at least 1 year and in good control (HbA1C less than or equal to 8.5%).~3. Be on continuous subcutaneous insulin infusion using an insulin pump.~4. Subjects must be otherwise healthy except for their T1DM and treated hypothyroidism.~5. Menstruating women must have a negative pregnancy test.~6. Hemoglobin equal to or greater than 12 g/dL before each study.~7. Weight more than 44 kg. -~Exclusion Criteria:~1. Age greater than 23 years or less than 13 years at the time of study~2. Any chronic disease: leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, etc or on treatment that might directly or indirectly affect glucose homeostasis, except for diabetes and hypothyroidism stable on medications~3. Anemia (hemoglobin less than 12mg/dl)~4. Lack of a supportive family environment~5. Positive pregnancy test in menstruating young women~6. Evidence or history of chemical abuse~7. Hgb A1C greater than 8.5 % in a diabetic subject~8. BMI \> 90 % tile for age or \< 10 % tile for age~9. Weight less than 44 kg. -

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese subjects at least 20 years of age at the time of informed consent~* Type 2 diabetes subjects (diagnosed clinically) for at least 6 months prior to screening~* HbA1c 7.5-10.0% \[58 mmol/mol-86 mmol/mol\] (both inclusive)~* Subjects on stable therapy with one OAD (oral antidiabetic drug) (stable therapy is defined as unchanged medication and unchanged dose) for for at least 60 days before screening according to approved Japanese labelling~Exclusion Criteria:~* Treatment with insulin within 12 weeks prior to screening~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening~* Screening calcitonin equal or above 50 ng/l~* History of pancreatitis (acute or chronic)~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV~* Within the past 180 days any of the following: myocardial infarction, stroke or hospitalisation for unstable angina and/or transient ischemic attack~* Diagnosis of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer, polyps and in-situ carcinomas)~* Any condition which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide 1.8 mg (Type: EXPERIMENTAL): The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
- Liraglutide 0.9 mg (Type: ACTIVE_COMPARATOR): The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal eye exam except for refractive error at baseline.~* Myopia should not exceed -4.00 Diopters (sphere) and 3.00 diopters of astigmatism, with spherical equivalent not higher than -4.50, confirmed by manifest refraction at baseline.~Exclusion Criteria:~* Monocular patient (including amblyopia) or best corrected visual acuity score worse than 20/80 (Snellen) or 55 letters (EDTRS), at baseline.~* Any systemic or ocular disease that might affect wound healing (such as severe rheumatoid arthritis or diabetes or history of keloid formation) or a history of ocular trauma, uveitis, infection, or inflammation in the 6 months prior to baseline.~* Previous refractive or corneal surgery (such as LASIK, PRK, radial keratotomy, pterygium removal, corneal transplantation).~* Chronic pain of any etiology or any significant illness which has not resolved within two (2) weeks prior to initial dosing.~Other inclusion and exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): None
- Treatment Sequence 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization~* 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase~* Currently treated with up to three established AEDs~* Vagal Nerve Stimulator may be included~Exclusion Criteria:~* Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study~* Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests~* Impaired renal function (creatinine clearance less than 50 mL/minute)~* Evidence of progressive central nervous disease, lesion, or encephalopathy~* History of primary generalized seizures~* History of clustering or flurries or status epilepticus within 12 months of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Retigabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post Traumatic Stress Disorder by Early Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adults survivors of traumatic events~Exclusion Criteria:~* Traumatic brain injury~* Lifetime psychosis~* Life time (prior) PTSD~* Medical conditions forbidding SSRIs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prolonged Exposure (CBT) (Type: EXPERIMENTAL): Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
- Cognitive Therapy (Type: ACTIVE_COMPARATOR): Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
- SSRI (escitalopram) (Type: EXPERIMENTAL): Twenty milligrams daily of escitalopram (blinded capsules)
- Placebo (Type: PLACEBO_COMPARATOR): Two concealed placebo pills resembling 10mg escitalopram tablets
- Waiting List (Type: NO_INTERVENTION): Twelve weeks of waiting list no intervention group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Compliant and satisfactory completion of Enobia-sponsored clinical trial ENB-006-09~* Written informed consent by parent or other legal guardian prior to any study procedures being performed~* Parent or other legal guardian willing to comply with study requirements~Exclusion Criteria:~* Clinically significant disease that precludes study participation, in the Investigator's opinion~* Treatment with an investigational drug other than asfotase alfa~* Enrollment in any study (other than ENB-006-09) involving an investigational drug, device, or treatment for HPP~* Prior treatment with bisphosphonates

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- asfotase alfa (Type: EXPERIMENTAL): asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* histologically confirmed grade 1, 2 or 3a follicular non-Hodgkin's lymphoma;~* patients who have received adequate (\>=8 cycles) induction therapy with MabThera as first line treatment, or treatment for relapsed disease;~* demonstrated partial or complete response to induction therapy.~Exclusion Criteria:~* stable or progressive disease after most recent induction therapy;~* transformation to high grade lymphoma;~* patients with prior or concomitant malignancies, except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete